204 related articles for article (PubMed ID: 34716691)
1. Paraspeckle Protein NONO Promotes TAZ Phase Separation in the Nucleus to Drive the Oncogenic Transcriptional Program.
Wei Y; Luo H; Yee PP; Zhang L; Liu Z; Zheng H; Zhang L; Anderson B; Tang M; Huang S; Li W
Adv Sci (Weinh); 2021 Dec; 8(24):e2102653. PubMed ID: 34716691
[TBL] [Abstract][Full Text] [Related]
2. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.
Lu Y; Wu T; Gutman O; Lu H; Zhou Q; Henis YI; Luo K
Nat Cell Biol; 2020 Apr; 22(4):453-464. PubMed ID: 32203417
[TBL] [Abstract][Full Text] [Related]
3. Truncated TEAD-binding protein of TAZ inhibits glioma survival through the induction of apoptosis and repression of epithelial-mesenchymal transition.
Zhao W; Li LW; Tian RF; Dong QF; Li PQ; Yan ZF; Yang X; Huo JL; Fei Z; Zhen HN
J Cell Biochem; 2019 Oct; 120(10):17337-17344. PubMed ID: 31209945
[TBL] [Abstract][Full Text] [Related]
4. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO.
Chen Y; Xu X; Ding K; Tang T; Cai F; Zhang H; Chen Z; Qi Y; Fu Z; Zhu G; Dou Z; Xu J; Chen G; Wu Q; Ji J; Zhang J
J Exp Clin Cancer Res; 2024 Feb; 43(1):39. PubMed ID: 38303029
[TBL] [Abstract][Full Text] [Related]
5. The role of transcriptional coactivator TAZ in gliomas.
Li W; Dong S; Wei W; Wang G; Zhang A; Pu P; Jia Z
Oncotarget; 2016 Dec; 7(50):82686-82699. PubMed ID: 27764783
[TBL] [Abstract][Full Text] [Related]
6. A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells.
Yamamoto K; Goyama S; Asada S; Fujino T; Yonezawa T; Sato N; Takeda R; Tsuchiya A; Fukuyama T; Tanaka Y; Yokoyama A; Toya H; Kon A; Nannya Y; Onoguchi-Mizutani R; Nakagawa S; Hirose T; Ogawa S; Akimitsu N; Kitamura T
Cell Rep; 2021 Aug; 36(8):109576. PubMed ID: 34433054
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas.
Escoll M; Lastra D; Pajares M; Robledinos-Antón N; Rojo AI; Fernández-Ginés R; Mendiola M; Martínez-Marín V; Esteban I; López-Larrubia P; Gargini R; Cuadrado A
Redox Biol; 2020 Feb; 30():101425. PubMed ID: 31918259
[TBL] [Abstract][Full Text] [Related]
8. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
9. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
10. Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ.
Liu Z; Wei Y; Zhang L; Yee PP; Johnson M; Zhang X; Gulley M; Atkinson JM; Trebak M; Wang HG; Li W
Oncogene; 2019 Jan; 38(1):120-139. PubMed ID: 30082911
[TBL] [Abstract][Full Text] [Related]
11. Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention.
Wang X; Han M; Wang S; Sun Y; Zhao W; Xue Z; Liang X; Huang B; Li G; Chen A; Li X; Wang J
Theranostics; 2022; 12(12):5451-5469. PubMed ID: 35910786
[No Abstract] [Full Text] [Related]
12. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract][Full Text] [Related]
13. Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression.
Li D; Chen Y; Mei H; Jiao W; Song H; Ye L; Fang E; Wang X; Yang F; Huang K; Zheng L; Tong Q
Oncogene; 2018 Aug; 37(35):4871-4886. PubMed ID: 29773901
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
15. Pro-oncogenic Roles of HLXB9 Protein in Insulinoma Cells through Interaction with Nono Protein and Down-regulation of the c-Met Inhibitor Cblb (Casitas B-lineage Lymphoma b).
Desai SS; Kharade SS; Parekh VI; Iyer S; Agarwal SK
J Biol Chem; 2015 Oct; 290(42):25595-608. PubMed ID: 26342078
[TBL] [Abstract][Full Text] [Related]
16. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
17. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.
Kim J; Kwon H; Shin YK; Song G; Lee T; Kim Y; Jeong W; Lee U; Zhang X; Nam G; Jeung HC; Kim W; Jho EH
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13529-13540. PubMed ID: 32482852
[TBL] [Abstract][Full Text] [Related]
18. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein p54
Shen M; Zhang R; Jia W; Zhu Z; Zhao L; Huang G; Liu J
Cell Death Dis; 2022 Jan; 13(1):42. PubMed ID: 35013116
[TBL] [Abstract][Full Text] [Related]
20. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma.
Li J; Li Z; Wu Y; Wang Y; Wang D; Zhang W; Yuan H; Ye J; Song X; Yang J; Jiang H; Cheng J
Cell Death Dis; 2019 Aug; 10(8):603. PubMed ID: 31399556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
